Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.65 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | MAT2A | P31153 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816460 | 1.00 | PDE4B (0.65) | PDE4BGGPS1NR3C1PDE5AMAT2A | |
| SCHEMBL4808317 | 0.89 | PDE4B (0.59) | PDE4BNR3C1PDE5AMAT2A | |
| SCHEMBL4809814 | 0.87 | PDE4B (0.58) | PDE4BNR3C1PDE5A | |
| SCHEMBL4808468 | 0.84 | PDE4B (0.67) | PDE4BGGPS1NR3C1PDE5A | |
| SCHEMBL13987114 | 0.83 | PDE4B (0.54) | PDE4BNR3C1PDE5A | |
| SCHEMBL13987116 | 0.83 | PDE4B (0.54) | PDE4BNR3C1PDE5A | |
| SCHEMBL4341484 | 0.82 | PDE4B (0.88) | PDE4B | |
| SCHEMBL14115728 | 0.82 | PDE4B (0.64) | PDE4BGGPS1NR3C1MAT2A | |
| SCHEMBL4819027 | 0.82 | PDE4B (0.49) | PDE4BNR3C1PDE5A | |
| SCHEMBL4344169 | 0.81 | PDE4B (0.63) | PDE4BNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465743-B2 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-12-16 | — | — | US | claimed |
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | claimed |
| US-7465743-B2 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | PDE3B, PDE3A, PDE4A | PDE4B 4/4885GGPS1 2595/4885NR3C1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.